Insights

IBSA invests in women’s health with the launch of Hyaluxelle®

Technology, science and culture are fundamental aspects of IBSA’s commitment to offering an effective and pragmatic approach to the needs of patients; placing the patient at the centre means first and foremost celebrating their individuality, and recognising their unique and specific nature.

In this sense, the world of women’s health has always been a privileged driver of investment for the company, which has, over the years, focused increasing attention on solutions dedicated to improving not only the health, but also the quality of life of female patients.

Although some progress has been made, differences still remain in levels of attention and investment which, on a global scale, see women’s health penalised. A recent study by McKinsey & Company maintains that women experience an average of 9 more years of poor health than men, above all in the working age population.

IBSA has recently launched Hyaluxelle®, a solution for adult women that helps patients suffering from genitourinary syndrome of menopause (GSM), of which one of the symptoms is vulvovaginal atrophy (VVA).

This is a condition that affects up to 90% of post-menopausal women, and to which IBSA responds in three ways:

  1. Scientific research and innovative biofermentation treatments

Hyaluxelle® can be seen as the result of a combination of research, innovation and commitment to improving the lives of patients, as it is composed of a solution of hyaluronic acid (HA) of high molecular weight (H-HA) and low molecular weight (L-HA) obtained through biofermentation and without the use of chemical modification techniques, resulting in excellent product tolerance and elevated biocompatibility.

  1. Innovation and patented technology

IBSA research is combined with innovative technology, thanks to a specific and patented treatment, NAHYCO® Hybrid Technology, which results in unique rheological properties that allow for higher concentrations of HA to be delivered without any increase in solution viscosity.

  1. Quality of life

Lastly, IBSA has also focused on rendering products simple to use, with pre-filled syringes that guarantee the utmost comfort.

Hyaluxelle® is the result of an overall commitment to developing solutions for women’s health that are effective, created to offer a pragmatic response to their needs while also designed to minimise therapy related stress, significantly improving quality of life for the patient.

Find out more in the virtual room dedicated to Hyaluxelle®

Discover Hyaluxelle®
Related Articles
+
30.07.2025
IBSA COMO PROTAGONISTA EN EL CPHI DE FRANKFURT
IBSA estará presente un año más en el CPHI de Frankfurt, uno de los eventos más importantes de la industria farmacéutica europea e internacional, programado del 28 al 30 de octubre. IBSA ha destacado siempre en el sector por el alto grado de innovación de sus soluciones en el ámbito farmacéutico, y no es casualidad que sea protagonista en la<div class="h10"></div><a class="more-link1" href="https://www.businessdevelopment.ibsagroup.com/news-eventi/ibsa-invests-in-womens-health-with-the-launch-of-hyaluxelle/">Read more</a>
+
30.07.2025
IBSA CENTRE STAGE AT CPHI IN FRANKFURT
IBSA will be present again this year at CPHI in Frankfurt, one of the most important events in the European and global pharmaceutical world, which will be held from the 28 to 30 of October. IBSA has always stood out in the sector for the high degree of innovation of its solutions in the pharmaceutical sector and, not surprisingly, will<div class="h10"></div><a class="more-link1" href="https://www.businessdevelopment.ibsagroup.com/news-eventi/ibsa-invests-in-womens-health-with-the-launch-of-hyaluxelle/">Read more</a>
+
15.07.2025
PEROVIAL®: EL ÉXITO DE LA INVESTIGACIÓN DE IBSA PARA LA SALUD HUMANA
We’re looking for partners and international distributors for our products.
GET IN TOUCH WITH US
logo-footer

Headquarter

 

Via del Piano 29,
6926 Collina d’Oro,
Switzerland
Tel. +41 58 360 10 00

 

 

Follow us

Linkedin
Facebook
Youtube